Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United Kingdom.
Independent Bioinformatics Consultant, Del Mar, California, USA.
Stem Cells Dev. 2023 Jul;32(13-14):387-397. doi: 10.1089/scd.2023.0043. Epub 2023 Jun 22.
Transplantation of human induced pluripotent stem cell-derived dopaminergic (iPSC-DA) neurons is a promising therapeutic strategy for Parkinson's disease (PD). To assess optimal cell characteristics and reproducibility, we evaluated the efficacy of iPSC-DA neuron precursors from two individuals with sporadic PD by transplantation into a hemiparkinsonian rat model after differentiation for either 18 (d18) or 25 days (d25). We found similar graft size and dopamine (DA) neuron content in both groups, but only the d18 cells resulted in recovery of motor impairments. In contrast, we report that d25 grafts survived equally as well and produced grafts rich in tyrosine hydroxylase-positive neurons, but were incapable of alleviating any motor deficits. We identified the mechanism of action as the extent of neurite outgrowth into the host brain, with d18 grafts supporting significantly more neurite outgrowth than nonfunctional d25 grafts. RNAseq analysis of the cell preparation suggests that graft efficacy may be enhanced by repression of differentiation-associated genes by REST, defining the optimal predifferentiation state for transplantation. This study demonstrates for the first time that DA neuron grafts can survive well in vivo while completely lacking the capacity to induce recovery from motor dysfunction. In contrast to other recent studies, we demonstrate that neurite outgrowth is the key factor determining graft efficacy and our gene expression profiling revealed characteristics of the cells that may predict their efficacy. These data have implication for the generation of DA neuron grafts for clinical application.
人诱导多能干细胞源性多巴胺能(iPSC-DA)神经元移植是治疗帕金森病(PD)的一种很有前途的治疗策略。为了评估最佳的细胞特征和可重复性,我们通过分化 18 天(d18)或 25 天(d25)后,将来自两名散发性 PD 患者的 iPSC-DA 神经元前体细胞移植到半帕金森大鼠模型中,评估其功效。我们发现两组的移植物大小和多巴胺(DA)神经元含量相似,但只有 d18 细胞导致运动障碍的恢复。相比之下,我们报告说 d25 移植物同样存活良好,并产生富含酪氨酸羟化酶阳性神经元的移植物,但无法缓解任何运动缺陷。我们确定了作用机制是轴突生长到宿主大脑的程度,d18 移植物支持的轴突生长明显多于无功能的 d25 移植物。细胞制备的 RNAseq 分析表明,通过 REST 抑制分化相关基因的表达可以增强移植物的功效,确定了移植的最佳预分化状态。这项研究首次表明,DA 神经元移植物在体内可以很好地存活,而完全没有诱导运动功能障碍恢复的能力。与其他最近的研究不同,我们证明了轴突生长是决定移植物功效的关键因素,我们的基因表达谱揭示了可能预测其功效的细胞特征。这些数据对生成用于临床应用的 DA 神经元移植物具有重要意义。